Put a little doxy-PEP in your step: Using doxycycline to prevent chlamydia, syphilis, and gonorrhea infections

Eric A. Meyerowitz,Rina Liang,Derek Bishop,Caroline E. Mullis

DOI: https://doi.org/10.1371/journal.ppat.1012575

IF: 7.464

2024-10-01

PLoS Pathogens

Abstract:In 2012, the United States Food and Drug Administration (FDA) approved tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis (PrEP) to prevent HIV infections in the US, revolutionizing sexual health care and prevention [1]. Comprehensive sexual health clinics have been offering a variety of treatment and prevention strategies since that time (Table 1), though prevention options for bacterial sexually transmitted infections (STIs) like chlamydia, syphilis, and gonorrhea have lagged. On June 6, 2024, the US Centers for Disease Control and Prevention (CDC) recommended doxycycline post-exposure prophylaxis (doxy-PEP) to prevent chlamydia, syphilis, and gonorrhea infections for gay, bisexual, and other men who have sex with men (MSM) and transgender women (TGW) who have had a bacterial STI diagnosed in the past 12 months [2]. The efficacy of doxycycline prophylaxis was shown in a US-based multicenter open label randomized trial including 501 MSM and TGW (including 174 living with HIV infection and 327 on PrEP) with at least 1 bacterial STI in the 12 months preceding enrollment [3]. Participants in the doxy-PEP arm were instructed to take a single dose of 200 mg of doxycycline within 72 hours (but ideally around 24 hours) after condomless sex. The primary endpoint was incidence of chlamydia, syphilis, or gonorrhea infections during follow-up, with a median follow-up period of 270 days. The relative risk reductions for chlamydia, gonorrhea, and syphilis infections were 0.12 (95% CI 0.05 to 025), 0.13 (95% CI 0.03 to 0.59), and 0.45 (95% CI 0.32 to 0.65) for people on PrEP and 0.26 (95% CI 0.12 to 0.57), 0.23 (95% CI 0.04 to 1.29), and 0.43 (95% CI 0.26 to 0.71) for people living with HIV infection. Participants were instructed to take no more than 200 mg doxycycline every 24 hours, with 86% of participants reporting consistent use of doxy-PEP after condomless sex and a median number of 4.0 doses per month (IQR 1.0 to 10.0). Two other randomized French studies also demonstrated the efficacy of doxy-PEP at preventing bacterial STIs in MSM and TGW [4,5]. To date, the only study testing doxy-PEP in cisgender women enrolled 449 women in Kenya and found no benefit, but poor adherence may explain these findings as only 29% of participants in the doxycycline arm had evidence of doxycycline in hair samples [6,7]. However, with a median of just 4 doses per month, it is not clear that doxycycline hair levels is the best assessment of appropriate adherence to intermittent and irregular doxycycline dosing [8].

microbiology,virology,parasitology